Pharma Alchemy: Oncology Beyond Conventional Formulations

November 29, 2023

A CMO/CDMO pharma company, valued at 700 Cr Mcap and boasting a 20% CAGR over the past decade, is venturing into the Oncology Segment with a substantial 194 Crore capex (FY23 Networth: 173 Crores). This dynamic entity is raising funds through several Preferential issues, with a notable investment from a major industry giant in India …